| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
82,823,000 |
| Market
Cap: |
1.74(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$18.92 - $29.92 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 484 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Veracyte is a genomic diagnostics company. Co. develops tests that address clinical needs in the diagnosis, prognosis and treatment of cancer and other diseases. Co. provides tests in: thyroid cancer via its Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas; prostate cancer via its Decipher Biopsy and Radical Prostatectomy Genomic Classifiers; breast cancer via its Prosigna Breast Cancer Assay; lung cancer via its Percepta GSC and Percepta Nasal Swab Test; interstitial lung diseases including idiopathic pulmonary fibrosis via its Envisia Genomic Classifier; bladder cancer via its Decipher Bladder Genomic Classifier; and colon cancer via its Immunoscore Colon Cancer Test.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
21,779 |
31,779 |
114,409 |
523,205 |
| Total Sell Value |
$459,589 |
$703,188 |
$3,171,383 |
$13,848,977 |
| Total People Sold |
2 |
3 |
4 |
6 |
| Total Sell Transactions |
5 |
6 |
15 |
32 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Chambers Rebecca |
Chief Financial Officer |
• – – |
2024-03-02 |
4 |
D |
$24.00 |
$146,688 |
D/D |
(6,112) |
84,717 |
|
- |
|
| Leite John |
Chief Commercial Officer-CLIA |
• – – |
2024-03-02 |
4 |
D |
$24.00 |
$72,192 |
D/D |
(3,008) |
35,679 |
|
- |
|
| Jones Evan/ Fa |
Director |
– • – |
2024-03-01 |
4 |
S |
$24.36 |
$243,599 |
D/D |
(10,000) |
37,601 |
|
9% |
|
| Jones Evan/ Fa |
Director |
– • – |
2024-03-01 |
4 |
OE |
$13.19 |
$131,900 |
D/D |
10,000 |
47,601 |
|
- |
|
| Leite John |
Chief Commercial Officer-CLIA |
• – – |
2023-12-02 |
4 |
D |
$26.54 |
$14,756 |
D/D |
(556) |
38,687 |
|
- |
|
| Stapley Marc |
Chief Executive Officer |
• • – |
2023-12-02 |
4 |
D |
$26.54 |
$85,008 |
D/D |
(3,203) |
221,882 |
|
- |
|
| Wygant Jonathan |
VP, Chief Accounting Officer |
• – – |
2023-12-02 |
4 |
D |
$26.54 |
$13,456 |
D/D |
(507) |
27,020 |
|
- |
|
| Chambers Rebecca |
Chief Financial Officer |
• – – |
2023-12-02 |
4 |
D |
$26.54 |
$47,772 |
D/D |
(1,800) |
90,829 |
|
- |
|
| Mcguire Annie |
SVP, General Counsel |
• – – |
2023-12-02 |
4 |
D |
$26.54 |
$21,312 |
D/D |
(803) |
51,792 |
|
- |
|
| Febbo Phillip G. |
Chief Scientific & Med Officer |
• – – |
2023-10-02 |
4 |
A |
$0.00 |
$0 |
D/D |
53,182 |
53,182 |
|
- |
|
| Leite John |
Chief Commercial Officer-CLIA |
• – – |
2023-09-02 |
4 |
D |
$26.70 |
$59,327 |
D/D |
(2,222) |
39,243 |
|
- |
|
| Stapley Marc |
Chief Executive Officer |
• • – |
2023-09-02 |
4 |
D |
$26.70 |
$85,547 |
D/D |
(3,204) |
225,085 |
|
- |
|
| Chambers Rebecca |
Chief Financial Officer |
• – – |
2023-09-02 |
4 |
D |
$26.70 |
$97,508 |
D/D |
(3,652) |
92,629 |
|
- |
|
| Mcguire Annie |
SVP, General Counsel |
• – – |
2023-09-02 |
4 |
D |
$26.70 |
$46,164 |
D/D |
(1,729) |
52,595 |
|
- |
|
| Wygant Jonathan |
VP, Chief Accounting Officer |
• – – |
2023-09-02 |
4 |
D |
$26.70 |
$33,295 |
D/D |
(1,247) |
27,527 |
|
- |
|
| Leite John |
Chief Commercial Officer-CLIAO |
• – – |
2023-09-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
41,465 |
|
1% |
|
| Jones Evan/ Fa |
Director |
– • – |
2023-07-19 |
4 |
AS |
$30.17 |
$93,232 |
I/I |
(3,090) |
35,173 |
|
-11% |
|
| Jones Evan/ Fa |
Director |
– • – |
2023-07-19 |
4 |
AS |
$30.14 |
$25,257 |
D/D |
(838) |
37,601 |
|
-11% |
|
| Jones Evan/ Fa |
Director |
– • – |
2023-07-18 |
4 |
AS |
$30.19 |
$224,616 |
I/I |
(7,441) |
38,263 |
|
-12% |
|
| Jones Evan/ Fa |
Director |
– • – |
2023-07-18 |
4 |
AS |
$30.16 |
$70,090 |
D/D |
(2,324) |
38,439 |
|
-12% |
|
| Bishop John L |
Director |
– • – |
2023-07-18 |
4 |
AS |
$30.50 |
$305,000 |
D/D |
(10,000) |
33,125 |
|
-12% |
|
| Bishop John L |
Director |
– • – |
2023-07-18 |
4 |
OE |
$6.37 |
$63,700 |
D/D |
10,000 |
43,125 |
|
- |
|
| Jones Evan/ Fa |
Director |
– • – |
2023-07-17 |
4 |
AS |
$30.07 |
$720,106 |
I/I |
(23,949) |
45,704 |
|
-16% |
|
| Jones Evan/ Fa |
Director |
– • – |
2023-07-17 |
4 |
AS |
$30.07 |
$574,106 |
D/D |
(19,095) |
40,763 |
|
-16% |
|
| Bishop John L |
Director |
– • – |
2023-07-17 |
4 |
AS |
$30.00 |
$300,002 |
D/D |
(10,000) |
33,125 |
|
-16% |
|
551 Records found
|
|
Page 2 of 23 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.82 (3.76%) 
